Richard A Krasuski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8689222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pulmonary Hypertension in Adults with Congenital Heart Disease. Cardiology Clinics, 2022, 40, 55-67.	2.2	6
2	Interventional Management of Chronic Thromboembolic Pulmonary Hypertension. Cardiology Clinics, 2022, 40, 103-114.	2.2	0
3	Pulmonary Hypertension. Cardiology Clinics, 2022, 40, xi-xii.	2.2	0
4	Burden and Impact of Arrhythmias in Repaired Tetralogy of Fallot. Current Cardiology Reports, 2022, 24, 225-234.	2.9	3
5	Utility of Cardiac Magnetic Resonance Imaging in Predicting Atrial Arrhythmias in Repaired Tetralogy of Fallot. American Journal of Cardiology, 2022, 174, 151-157.	1.6	1
6	Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 2101-2110.	1.7	5
7	Pregnancy in a woman with congenitally corrected transposition of the great arteries. Cleveland Clinic Journal of Medicine, 2021, 88, 228-236.	1.3	0
8	A multiscale model of vascular function in chronic thromboembolic pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H318-H338.	3.2	18
9	Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, 27, 2034-2041.	1.8	13
10	Hybrid transcatheter pulmonary valve replacement with a SAPIEN S3 valve after pulmonary artery banding via left lateral thoracotomy. Catheterization and Cardiovascular Interventions, 2020, 95, E78-E83.	1.7	7
11	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.8	26
12	Causes of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease. Journal of the American Heart Association, 2020, 9, e016400.	3.7	18
13	Deaths in pulmonary hypertension: US location trends. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002254.	1.6	1
14	The Evolving Surgical Burden of Fontan Failure: Insights from a Nationwide Surgical Database. Annals of Thoracic Surgery, 2020, 112, 179-187.	1.3	12
15	Mustard Baffle Revision With Systemic Ventricular Assist Device Placement. Annals of Thoracic Surgery, 2020, 110, e279-e280.	1.3	1
16	Approaching End-of-Life Decisions in Adults with Congenital Heart Disease. Current Cardiology Reports, 2020, 22, 173.	2.9	2
17	Intensive Care Unit Management of the Adult with Congenital Heart Disease. Current Cardiology Reports, 2020, 22, 136.	2.9	4
18	The LDL cholesterol in stroke limbo. Current Opinion in Lipidology, 2020, 31, 161-162.	2.7	1

#	Article	IF	CITATIONS
19	Deaths from heart failure and cancer: location trends. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002275.	1.6	3
20	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. American Journal of Cardiology, 2020, 130, 159-161.	1.6	23
21	Pulmonary Valve Endocarditis: The Potential Utility of Multimodal Imaging Prior to Surgery. World Journal for Pediatric & Congenital Heart Surgery, 2020, 11, 192-197.	0.8	3
22	Rate, Causes, and Predictors of 30-Day Readmission Following Hospitalization for Acute Pericarditis. American Journal of Medicine, 2020, 133, 1453-1459.e1.	1.5	4
23	Emergency department evaluation of chest pain among adult congenital heart disease patients. American Heart Journal, 2020, 222, 191-198.	2.7	6
24	Aspiration Thrombectomy Versus Stent Retriever Thrombectomy Alone for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cureus, 2020, 12, e8380.	0.5	4
25	Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. American Heart Journal, 2020, 230, 71-81.	2.7	6
26	Impact of Pulmonary Hypertension on Survival Following Device Closure of Atrial Septal Defects. American Journal of Cardiology, 2019, 124, 1460-1464.	1.6	8
27	Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes. JAMA Network Open, 2019, 2, e192622.	5.9	55
28	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension. Chest, 2019, 156, 53-63.	0.8	42
29	Assessing the Quality of Abstracts in Randomized Controlled Trials Published in High Impact Cardiovascular Journals. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005260.	2.2	17
30	Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. Respiratory Medicine, 2019, 150, 126-130.	2.9	12
31	Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 2019, 19, 465-476.	2.2	19
32	Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2019, 291, 134-139.	1.7	37
33	Fragility Index in Cardiovascular Randomized Controlled Trials. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005755.	2.2	35
34	Ask the Expert: Transplantation in Eisenmenger Syndrome: Getting to the Heart of the Matter. Advances in Pulmonary Hypertension, 2019, 18, 31-32.	0.1	1
35	Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials. American Heart Journal, 2018, 199, 44-50.	2.7	14
36	Effect of Patent Foramen Ovale in Patients With Pulmonary Hypertension. American Journal of Cardiology, 2018, 122, 505-510.	1.6	10

#	Article	IF	CITATIONS
37	A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. European Journal of Preventive Cardiology, 2018, 25, 844-853.	1.8	43
38	Branch Pulmonary Artery Valve Implantation Reduces Pulmonary Regurgitation and Improves Right Ventricular Size/Function in Patients With Large Right Ventricular Outflow Tracts. JACC: Cardiovascular Interventions, 2018, 11, 541-550.	2.9	21
39	Atheromatous disease of the aorta and perioperative stroke. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 508-516.	0.8	17
40	Adult Congenital Heart Disease Care Provision: the Need for a Jack/Jackie of All Trades. Progress in Cardiovascular Diseases, 2018, 61, 273-274.	3.1	1
41	Association Between Obesity and Cardiovascular Outcomes. JAMA Network Open, 2018, 1, e183788.	5.9	208
42	Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004757.	2.2	29
43	Long Term Consequences of the Fontan Procedure and How to Manage Them. Progress in Cardiovascular Diseases, 2018, 61, 365-376.	3.1	20
44	Transcatheter Valve Replacement for Right-sided Valve Disease in Congenital Heart Patients. Progress in Cardiovascular Diseases, 2018, 61, 347-359.	3.1	8
45	Exercise in Congenital Heart Disease. , 2018, , 221-265.		0
46	Coronary Disease and Modifying Cardiovascular Risk in Adult Congenital Heart Disease Patients: Should General Guidelines Apply?. Progress in Cardiovascular Diseases, 2018, 61, 300-307.	3.1	18
47	A Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease. Progress in Cardiovascular Diseases, 2018, 61, 320-327.	3.1	6
48	Heart Transplantation and Mechanical Circulatory Support in Adults with Congenital Heart Disease. Current Cardiology Reports, 2018, 20, 81.	2.9	12
49	Deep thoughts on lipids and cognition. Current Opinion in Lipidology, 2017, 28, 288-289.	2.7	0
50	Characteristics of pediatric pulmonary hypertension trials registered on ClinicalTrials.gov. Pulmonary Circulation, 2017, 7, 348-360.	1.7	7
51	Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. American Journal of Cardiology, 2017, 120, 774-781.	1.6	40
52	Evaluation of Industrial Compensation to Cardiologists in 2015. American Journal of Cardiology, 2017, 120, 2294-2298.	1.6	7
53	Pulmonic Valve Disease: Review of Pathology and Current Treatment Options. Current Cardiology Reports, 2017, 19, 108.	2.9	36
54	Best Practice Advisories Should Not Replace Good Clinical Acumen. American Journal of Medicine, 2017, 130, 245-246.	1.5	6

#	Article	IF	CITATIONS
55	Health insurance and racial disparities in pulmonary hypertension outcomes. American Journal of Managed Care, 2017, 23, 474-480.	1.1	16
56	ls it time to reconsider combination lipid therapy in high-risk diabetic patients?. Current Opinion in Lipidology, 2016, 27, 310-311.	2.7	0
57	Contributors to and impact of residual shunting after device closure of atrial septal defects. American Heart Journal, 2016, 177, 112-119.	2.7	5
58	Two Cases of Late Shone Syndrome With Pulmonary Hypertension. World Journal for Pediatric & Congenital Heart Surgery, 2016, 7, 100-103.	0.8	2
59	Extra-cardiac manifestations of adult congenital heart disease. Trends in Cardiovascular Medicine, 2016, 26, 627-636.	4.9	20
60	Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 294-302.	2.2	20
61	Congenital Heart Disease Epidemiology in the United States. Circulation, 2016, 134, 110-113.	1.6	55
62	Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs?. American Journal of Cardiology, 2016, 117, 1851-1852.	1.6	2
63	Conflicts of Interest and Outcomes of Cardiovascular Trials. American Journal of Cardiology, 2016, 117, 858-860.	1.6	11
64	Impact of Diabetes in Patients with Pulmonary Hypertension. Pulmonary Circulation, 2015, 5, 117-123.	1.7	42
65	Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials. American Journal of Cardiology, 2015, 116, 1944-1947.	1.6	29
66	Isolated Noncompaction of theÂLeftÂVentricle in Adults. Journal of the American College of Cardiology, 2015, 66, 578-585.	2.8	98
67	Therapy and clinical trials. Current Opinion in Lipidology, 2015, 26, 70-71.	2.7	0
68	Abstract 16300: Efficacy and Safety of Anticoagulation Following Bioprosthetic Aortic Valve Replacement: A Meta-analysis. Circulation, 2015, 132, .	1.6	0
69	Abstract 14217: Subsequent Sustained Ventricular Arrhythmia in Patients With Transposition of the Great Arteries Undergoing Device Implantation. Circulation, 2015, 132, .	1.6	0
70	Incremenal Value of Cardiac Magnetic Resonance for Assessing Pulmonic Valve Regurgitation. Journal of Heart Valve Disease, 2015, 24, 502-7.	0.5	3
71	Changes in Echo Measures With Therapy Predict Improved Outcome in Pulmonary Arterial Hypertension. Chest, 2014, 146, 841A.	0.8	0
72	Therapy and clinical trials. Current Opinion in Lipidology, 2014, 25, 410-411.	2.7	0

#	Article	IF	CITATIONS
73	Pharmacologic Management of Perioperative Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2014, 63, 375-384.	1.9	13
74	Comparison of Long-Term Postoperative Sequelae in Patients With Tetralogy of Fallot Versus Isolated Pulmonic Stenosis. American Journal of Cardiology, 2014, 114, 300-304.	1.6	14
75	Inhaled treprostinil sodium for pulmonary hypertension. Expert Opinion on Orphan Drugs, 2014, 2, 283-291.	0.8	0
76	Endovascular Treatment of Congenital Pulmonary Artery Lesions. , 2014, , 1071-1092.		0
77	Tricuspid regurgitation and right ventricular function after mitral valve surgery with or without concomitant tricuspid valve procedure. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1126-1132.e10.	0.8	117
78	PINOT NOIR: Pulmonic INsufficiency imprOvemenT with Nitric Oxide Inhalational Response. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 75.	3.3	8
79	Therapy and clinical trials. Current Opinion in Lipidology, 2013, 24, 281-282.	2.7	1
80	Aorta–to–Pulmonary Vein Fistula in an Asymptomatic 25-Year-Old Man. Circulation, 2013, 127, 1727-1729.	1.6	6
81	Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome. Hepatology, 2013, 58, 1514-1515.	7.3	12
82	Embolization of patent foramen ovale closure devices: incidence, role of imaging in identification, potential causes, and management. Texas Heart Institute Journal, 2013, 40, 439-44.	0.3	14
83	Lateral caval flap repair of adult sinus venosus atrial septal defect: A natural novel approach. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 984-985.	0.8	8
84	Congenital Heart Disease and Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, 427-445.	2.1	12
85	Effect of Obesity on B-Type Natriuretic Peptide Levels in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 909-914.	1.6	12
86	Provoked Exercise Desaturation in Patent Foramen Ovale and Impact of Percutaneous Closure. JACC: Cardiovascular Interventions, 2012, 5, 416-419.	2.9	41
87	PINOT NOIR: Pulmonic INsufficiency imprOvemenT with Nitric Oxide Inhalational Response. Journal of Cardiovascular Magnetic Resonance, 2012, 14, .	3.3	0
88	Pulmonary Vein Isolation for the Treatment of Drug-Refractory Atrial Fibrillation in Adults with Congenital Heart Disease. Congenital Heart Disease, 2012, 7, 392-399.	0.2	65
89	Partial anomalous pulmonary venous connection and pulmonary arterial hypertension. Respirology, 2012, 17, 957-963.	2.3	37
90	Off-label closure during CLOSURE study. Journal of Invasive Cardiology, 2012, 24, 608-11.	0.4	6

#	Article	IF	CITATIONS
91	Downstream coronary effects of drug-eluting stents. American Heart Journal, 2011, 162, 764-771.e1.	2.7	6
92	Response to Inhaled Nitric Oxide Predicts Survival in Patients With Pulmonary Hypertension. Journal of Cardiac Failure, 2011, 17, 265-271.	1.7	19
93	Association of anemia and long-term survival in patients with pulmonary hypertension. International Journal of Cardiology, 2011, 150, 291-295.	1.7	44
94	Partial Anomalous Pulmonary Venous Connection and Pulmonary Hypertension. Chest, 2011, 140, 735A.	0.8	0
95	The Effect of Gemfibrozil, Niacin and Cholestyramine Combination Therapy on Metabolic Syndrome in the Armed Forces Regression Study. American Journal of the Medical Sciences, 2011, 341, 378-382.	1.1	6
96	Modified INOvent for delivery of inhaled nitric oxide during cardiac MRI. Magnetic Resonance Imaging, 2011, 29, 1145-1149.	1.8	5
97	Therapy and clinical trials. Current Opinion in Lipidology, 2011, 22, 512-513.	2.7	Ο
98	Long-Term Outcome and Impact of Surgery on Adults With Coronary Arteries Originating From the Opposite Coronary Cusp. Circulation, 2011, 123, 154-162.	1.6	129
99	Response to Letter Regarding Article, "Long-Term Outcome and Impact of Surgery on Adults With Coronary Arteries Originating From the Opposite Coronary Cusp― Circulation, 2011, 124, .	1.6	1
100	Is There a Role for Acute Vasoreactivity Testing Outside of Patients With Pulmonary Arterial Hypertension?. Advances in Pulmonary Hypertension, 2011, 10, 15-16.	0.1	0
101	Right-Sided Heart Catheterization. Chest, 2010, 138, 1030-1032.	0.8	3
102	Therapy and clinical trials. Current Opinion in Lipidology, 2010, 21, 471-472.	2.7	2
103	Effect of Motorized Scooters on Quality of Life and Cardiovascular Risk. American Journal of Cardiology, 2010, 105, 672-676.	1.6	23
104	Impact of Increases in High-Density Lipoprotein Cholesterol on Cardiovascular Outcomes During the Armed Forces Regression Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 380-383.	2.0	4
105	Impact of Fibrinogen Levels on Angiographic Progression and 12-Year Survival in the Armed Forces Regression Study. Angiology, 2010, 61, 333-337.	1.8	6
106	DOWNSTREAM CORONARY EFFECTS OF DRUG ELUTING STENTS: UNINTENDED THERAPEUTIC TARGET?. Journal of the American College of Cardiology, 2010, 55, A171.E1604.	2.8	0
107	When â€ ⁻ blue babies' grow up: What you need to know about tetralogy of Fallot. Cleveland Clinic Journal of Medicine, 2010, 77, 821-828.	1.3	10
108	Congenital Heart Disease in the Adult 2010 212-222 el		2

#	Article	IF	CITATIONS
109	Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. Journal of Heart Valve Disease, 2010, 19, 708-15.	0.5	30
110	Incidence of Asymptomatic Patent Foramen Ovale According to Age. Annals of Internal Medicine, 2009, 150, 431.	3.9	13
111	Aneurysmal ascending to descending aorta bypass graft compressing the pulmonary artery. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 730-732.	1.1	1
112	Morphology of the Patent Foramen Ovale in Asymptomatic Versus Symptomatic (Stroke or Transient) Tj ETQq0	0 0 rgBT / 1.6	Overlock 10 T
113	Persistent Tricuspid Regurgitation and Its Predictor in Adults After Percutaneous and Isolated Surgical Closure of Secundum Atrial Septal Defect. American Journal of Cardiology, 2009, 104, 856-861.	1.6	29
114	Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). American Journal of Cardiology, 2009, 104, 1457-1464.	1.6	47
115	Therapy and clinical trials. Current Opinion in Lipidology, 2009, 20, 262-263.	2.7	Ο
116	Prevalence and Repair of Intraoperatively Diagnosed Patent Foramen Ovale and Association With Perioperative Outcomes and Long-term Survival. JAMA - Journal of the American Medical Association, 2009, 302, 290.	7.4	66
117	Exercise and Noncardiac Surgery in Valvular Heart Disease. , 2009, , 499-514.		0
118	A 37-year-old man with chest pain, ECG changes, and elevated cardiac enzymes. Cleveland Clinic Journal of Medicine, 2009, 76, 199-205.	1.3	0
119	ORIGINAL INVESTIGATIONS: Tissue Harmonic Imaging in Echocardiography: Better Valve Imaging, But at What Cost?. Echocardiography, 2008, 25, 119-123.	0.9	15
120	Primary Prevention and Statins: Is It Just About Going to Class?. Mayo Clinic Proceedings, 2008, 83, 1313-1315.	3.0	2
121	Therapy and clinical trials. Current Opinion in Lipidology, 2008, 19, 218-220.	2.7	2
122	Therapy and clinical trials. Current Opinion in Lipidology, 2008, 19, 550-551.	2.7	0
123	Evidence-based Medical Management of Pulmonary Hypertension 2008: Review of Updated 2007 ACCP Guidelines. Advances in Pulmonary Hypertension, 2008, 7, 222-227.	0.1	2
124	Takotsubo cardiomyopathy: an unusual syndrome mimicking an ST-elevation myocardial infarction. American Journal of Emergency Medicine, 2007, 25, 92-95.	1.6	13
125	When and how to fix a 'hole in the heart': approach to ASD and PFO Cleveland Clinic Journal of Medicine, 2007, 74, 137-147.	1.3	16
126	Patent Ductus Arteriosus Closure. Journal of Interventional Cardiology, 2006, 19, S60-S66.	1.2	3

#	Article	IF	CITATIONS
127	The cardiovascular patient's perceptions of complementary and alternative medicine. Clinical Cardiology, 2006, 29, 161-164.	1.8	27
128	Educational Attainment Has a Limited Impact on Disease Management Outcomes in Heart Failure. Disease Management: DM, 2006, 9, 157-166.	1.0	15
129	Late "adult form" scimitar syndrome presenting with "infant form" complications. Journal of Invasive Cardiology, 2006, 18, E82-5.	0.4	7
130	Peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon mitral valve commissurotomy. Journal of Heart Valve Disease, 2006, 15, 369-74.	0.5	2
131	HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. Current Opinion in Lipidology, 2005, 16, 652-657.	2.7	5
132	Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagulation and Fibrinolysis, 2005, 16, 173-176.	1.0	23
133	A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events. Annals of Internal Medicine, 2005, 142, 95.	3.9	205
134	Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study. Mayo Clinic Proceedings, 2005, 80, 1163-1168.	3.0	22
135	The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use. American Heart Journal, 2005, 150, 725-728.	2.7	10
136	The emerging role of percutaneous intervention in adults with congenital heart disease. Reviews in Cardiovascular Medicine, 2005, 6, 11-22.	1.4	6
137	Disease management produces limited quality-of-life improvements in patients with congestive heart failure: evidence from a randomized trial in community-dwelling patients. American Journal of Managed Care, 2005, 11, 701-13.	1.1	43
138	Cardiopulmonary and Mental Health Diagnoses Surrounding the September 11 Terrorist Acts in a Military Population. Military Medicine, 2004, 169, 675-680.	0.8	4
139	Long-Term Healthcare and Cost Outcomes of Disease Management in a Large, Randomized, Community-Based Population With Heart Failure. Circulation, 2004, 110, 3518-3526.	1.6	215
140	Matrix Metalloproteinases in Patients with Myocardial Infarction and Percutaneous Revascularization. Journal of Interventional Cardiology, 2004, 17, 27-31.	1.2	44
141	Usefulness of percutaneous balloon mitral commissurotomy in preventing the development of atrial fibrillation in patients with mitral stenosis. American Journal of Cardiology, 2004, 93, 936-939.	1.6	30
142	"lt's hard to make predictions, especially about the future― Catheterization and Cardiovascular Interventions, 2004, 61, 429.	1.7	0
143	Effects of Pre-Analytical Variables on the Anti-FXa Chromogenic Assay when Monitoring Unfractionated Heparin and Low Molecular Weight Heparin Anticoagulation Blood, 2004, 104, 4064-4064.	1.4	0
144	Utility of Magnetic Resonance Imaging in Cardiac Venous Anatomic Variants?. CardioVascular and Interventional Radiology, 2003, 26, 309-311.	2.0	6

#	Article	IF	CITATIONS
145	Trained and supervised physician assistants can safely perform diagnostic cardiac catheterization with coronary angiography. Catheterization and Cardiovascular Interventions, 2003, 59, 157-160.	1.7	19
146	C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. American Heart Journal, 2003, 146, 1099-1104.	2.7	25
147	Addition of right-sided and posterior precordial leads during stress testing. American Heart Journal, 2003, 146, 1090-1094.	2.7	5
148	Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. Journal of Invasive Cardiology, 2003, 15, 699-702.	0.4	58
149	Serial echocardiographic evaluation of restenosis after successful percutaneous mitral commissurotomy. Journal of the American College of Cardiology, 2002, 39, 328-334.	2.8	40
150	Critical pathways for patients with acute chest pain at low risk. Journal of Thrombosis and Thrombolysis, 2002, 13, 89-96.	2.1	29
151	Comparison of results of percutaneous balloon mitral commissurotomy in patients aged ≥65 years with those in patients aged <65 years. American Journal of Cardiology, 2001, 88, 994-1000.	1.6	6
152	Congenital agenesis of the right pulmonary artery. Catheterization and Cardiovascular Interventions, 2000, 51, 460-463.	1.7	6
153	Cardiac Rhabdomyoma in an Adult Patient Presenting With Ventricular Arrhythmia. Chest, 2000, 118, 1217-1221.	0.8	24
154	Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. Journal of the American College of Cardiology, 2000, 36, 2204-2211.	2.8	72
155	Weekend and holiday exercise testing in patients with chest pain. Journal of General Internal Medicine, 1999, 14, 10-14.	2.6	14